Streetbeat News

Analyst Ratings

HES

Hess Inc.'s stock price is currently at $141.20, after a 0.71% increase. However, the stock has fallen by 12.29% over the past month and by 2.96% over the past year. Hess's P/E ratio of 29.45 is higher than the aggregate P/E ratio of the Oil, Gas & Consumable Fuels industry, which is 8.52. This could indicate that the stock is overvalued, but it could also suggest that investors expect the company to perform better in the future.

Portfolio Pulse from Benzinga Insights

November 10, 2023 | 2:00 pm

CLDX

Over the past 3 months, 7 analysts have published their opinion on Celldex Therapeutics (NASDAQ:CLDX) stock. The company has an average price target of $48.86, a decrease of 23.06% from the previous average price target of $63.50. The ratings include 1 bullish, 4 somewhat bullish, 1 indifferent, and 1 somewhat bearish.

Portfolio Pulse from Benzinga Insights

November 10, 2023 | 2:00 pm

DCBO

Morgan Stanley analyst Josh Jennings has maintained an Overweight rating on Docebo (NASDAQ:DCBO) and raised the price target from $49 to $53.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 1:59 pm

CTVA

Morgan Stanley analyst Vincent Andrews has maintained an Overweight rating on Corteva (NYSE:CTVA) but lowered the price target from $80 to $60.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 1:57 pm

CRWD

GOOG

PWR

On CNBC's 'Halftime Report Final Trades', Alphabet Inc., Quanta Services, Inc., and CrowdStrike Holdings, Inc. were named as final trades. Alphabet's CEO is set to testify in an ongoing antitrust lawsuit with Epic Games. Quanta Services reported better-than-expected Q3 earnings and provided FY23 revenue and earnings guidance. CrowdStrike Holdings, which recently hit a 52-week high, is expected to release its Q3 2024 financial results soon.

Portfolio Pulse from Lisa Levin

November 10, 2023 | 1:57 pm

COMM

Morgan Stanley analyst Meta Marshall has maintained an Equal-Weight rating on CommScope Hldg Co (NASDAQ:COMM) and lowered the price target from $4.5 to $2.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 1:56 pm

OMGA

Wedbush analyst Robert Driscoll has maintained an Outperform rating on Omega Therapeutics (NASDAQ:OMGA), but lowered the price target from $19 to $12.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 1:56 pm

GBIO

Wedbush analyst David Nierengarten has maintained an Outperform rating on Generation Bio (NASDAQ:GBIO), but lowered the price target from $11 to $9.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 1:55 pm

CRL

Morgan Stanley analyst Ricky Goldwasser has maintained an Equal-Weight rating on Charles River (NYSE:CRL) and lowered the price target from $220 to $205.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 1:54 pm

BIIB

Morgan Stanley analyst Matthew Harrison maintains an Overweight rating on Biogen (NASDAQ:BIIB) and raises the price target from $361 to $373.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 1:53 pm